Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at Chardan Capital in a report issued on Tuesday,Benzinga reports. They presently have a $35.00 price objective on the stock. Chardan Capital’s price target indicates a potential upside of 18.40% from the stock’s current price.
A number of other research analysts also recently weighed in on the stock. The Goldman Sachs Group began coverage on shares of Stoke Therapeutics in a research report on Monday, July 13th. They issued a “buy” rating and a $44.00 price objective for the company. Weiss Ratings cut Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Finally, BTIG Research restated a “buy” rating and set a $39.00 target price on shares of Stoke Therapeutics in a research report on Monday, May 11th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Stoke Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $43.00.
Get Our Latest Analysis on STOK
Stoke Therapeutics Price Performance
Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). The firm had revenue of $9.32 million for the quarter, compared to analysts’ expectations of $4.89 million. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%. On average, sell-side analysts anticipate that Stoke Therapeutics will post -3.22 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, General Counsel Jonathan Allan sold 1,457 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total value of $43,637.15. Following the completion of the sale, the general counsel owned 18,086 shares of the company’s stock, valued at approximately $541,675.70. The trade was a 7.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Barry Ticho sold 1,795 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $30.58, for a total transaction of $54,891.10. Following the transaction, the insider owned 34,826 shares of the company’s stock, valued at $1,064,979.08. This represents a 4.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 9.60% of the company’s stock.
Institutional Trading of Stoke Therapeutics
Several institutional investors have recently modified their holdings of the stock. Kestra Advisory Services LLC purchased a new stake in shares of Stoke Therapeutics during the fourth quarter worth about $26,000. KBC Group NV purchased a new position in Stoke Therapeutics in the 1st quarter valued at about $36,000. Harbour Investments Inc. lifted its stake in Stoke Therapeutics by 312.9% in the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after buying an additional 898 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after buying an additional 1,668 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in Stoke Therapeutics by 461.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after buying an additional 3,591 shares during the last quarter.
About Stoke Therapeutics
Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.
The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.
Featured Stories
- Five stocks we like better than Stoke Therapeutics
- 3 Drone Stocks That Should Soar After the Summer Slump
- Tyson Foods Offers a Meaty Opportunity for Income Investors
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
